Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DANICSU
2024-512386-14-00Phase 2Completed
- Sponsor
- Fraunhofer Institute for Translational Medicine and Pharmacology
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of danicopan in chronic idiopathic urticaria (CIU), sponsored by Fraunhofer Institute for Translational Medicine and Pharmacology. Primary endpoint: Change in UAS7 from baseline to week 17 in patients with low total IgE (≤40 kU/L) and high total IgE (>40 kU/L). Started Sep 2024; status: completed.
02
Drugs
danicopan
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2024-512386-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512386-14-00.